Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- VLP and Shionogi 1st to Be Selected for SCARDA Vaccine Funding Program
July 4, 2022
- FDA Philippines to Expedite Review Process of Japan-Approved Drugs
July 1, 2022
- AMED Employees’ Annual Pay Averaged 9.3 Million Yen in FY2021
July 1, 2022
- Ryukaikon to Assess Situation of Products Distributed by Single Wholesalers
July 1, 2022
- MHLW Panel to Discuss Cultivation of Cannabis for Use as Pharmaceutical Ingredient
July 1, 2022
- Survey Finds 11.7% of Wholesaler Transactions Negotiated through Proxies: MHLW
June 30, 2022
- Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
- Average Annual Pay for PMDA Staffers at 7.7 Million Yen in FY2021
June 29, 2022
- MHLW Drafts Guidelines on Development of Recombinant Viral Vaccines
June 29, 2022
- Safety of Emergency Approval Products to Be Monitored with RMP: Official
June 27, 2022
- MHLW Panel OKs 56 More Health Damage Claims for COVID-19 Vaccines
June 27, 2022
- Japan Finds 4 More Probable Cases of Acute Hepatitis in Children
June 27, 2022
- PMDA Reviewing Safety Risks for Imfinzi and Bavencio
June 27, 2022
- Health Minister Visits Takeda Manufacturing Site for Novavax Jab, Stresses Need to Handle Diverse Modalities in Japan
June 24, 2022
- Japan Logs 496 Pharma Product Recalls in FY2021; Self-Inspections, COVID Drive Surge
June 24, 2022
- Industry Groups Seek Financial Aid for Securing Pandemic Response Supplies
June 23, 2022
- Pharma-Backed Upper House Candidates Kick Off Campaigning for July 10 Poll
June 23, 2022
- Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
- Takashi Yasukawa Named Pharmaceutical Management Director
June 22, 2022
- Govt Panel Agrees to Add Xofluza to Flu Drug Stockpile
June 22, 2022
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…